UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 14, 2010

SEQUENOM, INC.

(Exact Name of Registrant as Specified in Charter)

3595 JOHN HOPKINS COURT

SAN DIEGO, CALIFORNIA 92121

(Address of Principal Executive Offices)

(858) 202-9000

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

(e) At a meeting held on June 15, 2010, the Board of Directors of Sequenom, Inc., a Delaware corporation (“Sequenom”), added Paul V. Maier, its Chief Financial Officer, to Sequenom’s change in control severance benefit plan, which is more fully described under “Executive Compensation – Compensation Discussion and Analysis – Change in Control Severance Benefit Plan” in Sequenom’s proxy statement filed with the Securities and Exchange Commission on April 29, 2010, as a Tier II participant.

As discussed below in Item 5.07, at Sequenom’s 2010 Annual Meeting of Stockholders (the “Annual Meeting”) Sequenom’s stockholders approved an amendment to Sequenom’s 2006 Equity Incentive Plan to increase the number of shares of Sequenom’s common stock available for issuance under such plan by 3,000,000 shares.

On June 14, 2010, Sequenom held its Annual Meeting at which the stockholders (i) elected Ernst-Günter Afting, Kenneth F. Buechler, John A. Fazio, Harry F. Hixson, Jr., Richard A. Lerner, Ronald M. Lindsay and David Pendarvis as directors to hold office until Sequenom’s annual meeting of stockholders in 2011, (ii) approved an amendment to Sequenom’s 2006 Equity Incentive Plan to increase the number of shares of Sequenom’s common stock available for issuance under such plan by 3,000,000 shares, and (iii) ratified the selection by the Audit Committee of the Board of Directors (the “Audit Committee”) of Ernst & Young LLP as independent auditors of Sequenom for the fiscal year ending December 31, 2010.

Sequenom had 62,164,582 shares of common stock outstanding and entitled to vote as of the close of business on April 19, 2010, the record date for the Annual Meeting. At the Annual Meeting, 45,895,959 shares of common stock were present in person or represented by proxy for the three proposals indicated above. The following sets forth detailed information regarding the results of the voting at the Annual Meeting:

Proposal 1: The election of Ernst-Günter Afting, Kenneth F. Buechler, John A. Fazio, Harry F. Hixson, Jr., Richard A. Lerner, Ronald M. Lindsay and David Pendarvis as directors to hold office until Sequenom’s annual meeting of stockholders in 2011.

Proposal 2: To approve an amendment to Sequenom’s 2006 Equity Incentive Plan to increase the number of shares of Sequenom’s common stock available for issuance under such plan by 3,000,000 shares.

Proposal 3: To ratify the selection by the Audit Committee of Ernst & Young LLP as independent auditors of Sequenom for the fiscal year ending December 31, 2010.

2

Effective as of the election of the directors at the Annual Meeting, as discussed above in Item 5.07, the Board of Directors of Sequenom restructured the Audit Committee to be comprised of Ernst-Günter Afting, John A. Fazio and David Pendarvis, with Mr. Fazio serving as Chair.

At a meeting held on June 15, 2010, the Board of Directors of Sequenom changed the title for two of its executive officers. Mr. Maier was named as Sequenom’s Chief Financial Officer and Ronald M. Lindsay was named as Sequenom’s Senior Vice President of Research and Development. Mr. Maier previously held the title as Sequenom’s Interim Chief Financial Officer and Dr. Lindsay previously held the title as Sequenom’s Interim Senior Vice President of Research and Development.

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

4